-
1دورية أكاديمية
المؤلفون: satiri, Satiri, Anriani, Nurul, Pahamzah, John, Muhyidin, Asep
المصدر: JPSD (Jurnal Pendidikan Sekolah Dasar); Vol 10, No 1 (2024); 37-50 ; 2503-0558 ; 2540-9093 ; 10.30870/jpsd.v10i1
مصطلحات موضوعية: Evaluation, Catalyst Program, Analysis
وصف الملف: application/pdf
العلاقة: https://jurnal.untirta.ac.id/index.php/jpsd/article/view/23154/11925Test; https://jurnal.untirta.ac.id/index.php/jpsd/article/view/23154Test
الإتاحة: https://doi.org/10.30870/jpsd.v10i1.23154Test
https://doi.org/10.30870/jpsd.v10i1Test
https://jurnal.untirta.ac.id/index.php/jpsd/article/view/23154Test -
2
مصطلحات موضوعية: StartupDelta, Post-quantum cryptography, Quantum Algorithm, TNO, Catalyst program, Quantum technology, Quantum cryptography, Quantum computer, Market creation, NWO, Quantum communication, Human Capital, Lorentz Institute, Microsoft, Quantum software, Quantum sensing, QKD, Social dialogue, Quantum Delta NL, Ecosystem development, Cat program, QuTech, National agenda, QuSoft, QT/e, Quantum simulator, AMS-IX, Quantum internet, Research and innovation
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dris___00893::19bc7637ab72059658605acb71147a5dTest
http://resolver.tudelft.nl/uuid:42c5fe8b-10e7-48a3-bbda-6a844060e3f0Test -
3
المؤلفون: TNO, QuTech, QuSoft, QT/e, NWO, het Lorentz Instituut, AMS-IX, StartupDelta en Microsoft, m.m.v. EZK
مصطلحات موضوعية: StartupDelta, Post-quantum cryptography, Quantum Algorithm, TNO, Catalyst program, Quantum technology, Quantum cryptography, Quantum computer, Market creation, NWO, Quantum communication, Human Capital, Lorentz Institute, Microsoft, Quantum software, Quantum sensing, QKD, Social dialogue, Quantum Delta NL, Ecosystem development, Cat program, QuTech, National agenda, QuSoft, QT/e, Quantum simulator, AMS-IX, Quantum internet, Research and innovation
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::d6db6b5e0bcc3200068acdb9090fdaddTest
http://resolver.tudelft.nl/uuid:42c5fe8b-10e7-48a3-bbda-6a844060e3f0Test -
4دورية أكاديمية
المساهمون: FRANKLIN RESEARCH CENTER NORRISTOWN PA
المصدر: DTIC AND NTIS
مصطلحات موضوعية: Electrical and Electronic Equipment, Electric Power Production and Distribution, Computer Programming and Software, Test Facilities, Equipment and Methods, COMPUTER PROGRAMS, RESEARCH FACILITIES, PULSE GENERATORS, PULSES, TEST SETS, DIRECT CURRENT, SHORT PULSES, SWITCHES, HIGH VOLTAGE, VOLTAGE, LABORATORIES, WAVEFORM CATALYST PROGRAM, SIGNAL PROCESSING, DISPLAY SYSTEMS, ANALOG TO DIGITAL CONVERTERS
وصف الملف: text/html
-
5
المؤلفون: 劉俊呈
المساهمون: 林志侯
مصطلحات موضوعية: 第二型糖尿病, 酪氨酸去磷酸酶, 藥效基團, CATALYST軟體, DOCK軟體, Type II Diabetes, Protein Tyrosine Phosphatase 1B, PHARMACOPHORE, CATALYST PROGRAM, DOCK PROGRAM
الوقت: 37
وصف الملف: 155 bytes; text/html
العلاقة: 1. 潘文涵、傅茂祖 糖尿病之流行病學及病因、診斷、分類http://health91.bhp.doh.gov.tw/1-3-11.htmTest 2. Zimmet, P., Alberti, K. G. M. M. & Shaw, J. Global and societal implications of the diabetes epidemic. Nature. 2001 414, 782-787 3. Gavete ML, Martin MA, Alvarez C, Escriva F Maternal food restriction enhances insulin-induced GLUT-4 translocation and insulin signaling pathway in skeletal muscle from suckling rats. Endocrinology. 2005 May 19 4. Zeigerer, A., M. A. Lampson, D. D. Sabatini, M. Adesnik, M. Ren, and T. E. McGraw. GLUT4 retention in adipocytes requires two intracellular insulin-regulated transport steps. Mol. Biol. Cell. 2002 13, 2421-2435. 5. T. O. Johnson, J. Ermolieff, M. R. Jirousek. Protein Tyrosine Phosphatase 1B Inhibitors For Diabetes. Nature Rev. 2002 1, 696-709 6. Cheng, A., Dube, N., Gu, F & Tremblay, M. L. Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eur. J. Biochem. 2002 269, 1050-1059 7. Dixit M, Tripathi BK, Srivastava AK, Goel A. Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett. 2005 Jun 9 8. 陳香惠、陳基旺 電腦虛擬篩選 In Silico Virtual Screening 9. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des. 2001 15(5) 411-28 10. Schrodinger LLC.Portland, 2003. 11. The Cambridge Crystallographic Data Centre 12 Union Road, Cambridge, CB2 1EZ, UK, 12. Sybyl Tripos Associates: St. Louis, MO, 13. Catalyst, version 4.9 (software package); Accelrys, Inc. (previously known as Molecular Simulations, Inc.): San Diego, 2004. 14. H. S. Andersen et al. Discovery and SAR of a Novel Selective and Orally Bioavailable Nonpeptide Clallical Competitive Inhibitor Class of Protein Tyrosine Phosphatase 1B. J. Med. Chem. 2002 45, 4443-4459 15. DOCK 4.0 manual. http://dock.compbio.uscf.edu/dock4/dock4.htmlTest 16. Breadth Technology IDDS manual. http://www.breadth.com.twTest/ 17. Debnath AK. Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. J. Med. Chem. 2002 45, 41-53 18. Breadth Technology IDEA / PScore manual. http://www.breadth.com.twTest/ 19. X-Score on-line manual. http://sw16.im.med.umich.edu/software/xtool/manual/index.htmlTest 20. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995 8, 127-34 21. Debnath, A. k Generation of Predictive Pharmacophore Models for CCR5 Antagonists:Study with Piperidine- and Piperazine-Based Compounds as a New Class of HIV-1 Entry Inhibitors. J. Med. Chem. 2003 47 768 22. Bleasdale, J. E. et al. Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action. Biochemistry 2001 40, 5642–5654 23. Liu, G. et al. Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J Med Chem. 2003 46, 2093-103 24. Doman, T. N. et al. Molecular docking and high throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 2002 45, 2213–2221. 25. Burke, T. R., Kole, H. K. & Roller, P. P. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp. Biochem. Biophys. Res. Commun. 1994 204, 129–134 26. Matter H, Baringhaus KH, Naumann T, Klabunde T, Pirard B. Computational approaches towards the rational design of drug-like compound libraries. Comb Chem High Throughput Screen. 2001 4, 453-75 27. Andersen, H. S. et al. 2-(Oxalylamino)-Benzoic Acid is a General, Competitive Inhibitor of Protein- Tyrosine Phosphatases. J Biol Chem. 2000 275(10):7101-8. 28. Bourdeau A, Dube N, Tremblay ML. Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. Curr Opin Cell Biol. 2005 17, 203-9. 29. R. Wang, Y. Lu, S. Wang Comparative Evaluation of 11 Scoring Functions for Molecular Docking. J. Med. Chem. 2003 46, 2287-2303 30. Puius, Y. A. et al. Identification of a second aryl phosphate binding site in protein tyrosine phosphatase 1B:a paradigm for inhibitor design. Proc. Natl Acad. Sci. 1997 94, 13420-13425; http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/33341Test
-
6
المؤلفون: 盧建勝, Chien-Sheng Lu
المساهمون: 林志侯教授
مصطلحات موضوعية: C型肝炎病毒, 藥效基團, CATALYST軟體, HCV, PHARMACOPHORE, CATALYST PROGRAM
الوقت: 37
وصف الملف: 155 bytes; text/html
العلاقة: 1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science 1989 244, 359–362 2. Hoofnagle, J. H. Hepatitis C — the clinical spectrum of disease. Hepatology 1997 26, S15–S20 . 3. Willems, M., Metselaar, H. J., Tilanus, H. W., Schalm, S. W. & de Man, R. A. Liver transplantation and hepatitis C. Transplant Int. 2002 15, 61–72 4. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S121-7 5. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol.; 2000 242:55-84 6. Friebe, P., Lohmann, V., Krieger, N. & Bartenschlager, R. Sequences in the 5′?nontranslated region of hepatitis C virus required for RNA replication. J. Virol. 2001 75, 12047–12057 7. Reed, K. E. & Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Hep. C Viruses 2000 242, 55–84 8. Tan SL, Pause A, Shi Y, Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. Nat Rev Drug Discov. 2002 Nov;1(11):867-81 9. Shirota, Y. et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J. Biol. Chem. 2002 277, 11149–11155 10. Bartenschlager, R. & Lohmann, V. Replication of hepatitis C virus. J. Gen. Virol. 2000 81, 1631–1648 11. Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 1998 282, 938–941 12. Monazahian, M. et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 1999 57,223–229 13. Agnello, V., Abel, G., Elfahal, M., Knight, G. B. & Zhang, Q. X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 1999 96, 12766–12771 14. Bukh, J., Miller, R. H. & Purcell, R. H. Genetic heterogeneity of hepatitis C virus — quasispecies and genotypes. Semin.Liv. Dis. 1995 15, 41–63 15. Zein, N. N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 2000 13, 223–235 16. Farci, P. & Purcell, R. H. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin. Liv. Dis. 2000 20, 103–126 17. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol. 2000 Feb;74(4):2046-51 18. De Francesco, R. et al. Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines. Sem. Liv. Dis. 2000 20, 69–83 19. Yao, N. H., Reichert, P., Taremi, S. S., Prosise, W. W. & Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999 7, 1353–1363 20. Dymock, B. W., Jones, P. S. & Wilson, F. X. Novel approaches to the treatment of hepatitis C virus infection. Antivir. Chem. Chemother. 2000 11, 79–96 . 21. Ingallinella, P. et al. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry 2002 41, 5483–5492 22. Zhang, R. M., Durkin, J. P. & Windsor, W. T. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg. Med. Chem. Lett. 2002 12, 1005–1008 23. Bennett JM, Campbell AD, Campbell AJ, Carr MG, Dunsdon RM, Greening JR, Hurst DN, Jennings NS, Jones PS, Jordan S, Kay PB, O'Brien MA, King-Underwood J, Raynham TM, Wilkinson CS, Wilkinson TC, Wilson FX. The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase. Bioorg Med Chem Lett. 2001 Feb 12;11(3):355-7 24. Priestley ES, De Lucca I, Ghavimi B, Erickson-Viitanen S, Decicco CP. P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease. Bioorg Med Chem Lett. 2002 Nov 4; 12(21) : 3199-202 25. Slater MJ, Andrews DM, Baker G, Bethell SS, Carey S, Chaignot H, Clarke B, Coomber B, Ellis M, Good A, Gray N, Hardy G, Jones P, Mills G, Robinson E. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3359-62 26. Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139, USA 27. Boehringer Ingelheim (Canada) Ltd, Laval, Que´bec, H7S 2G5, Canada 28. Kolykhalov, A. A. et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997 277, 570–574 29. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des. 2001 May; 15(5):411-28 30. Schrödinger LLC.Portland, 2003. 31. The Cambridge Crystallographic Data Centre 12 Union Road, Cambridge, CB2 1EZ, UK, 32. Sybyl Tripos Associates: St. Louis, MO, 33. Catalyst, version 4.9 (software package); Accelrys, Inc. (previously known as Molecular Simulations, Inc.): San Diego, 2004. 34. Debnath, A. K Generation of Predictive Pharmacophore Models for CCR5 Antagonists: Study with Piperidine- and Piperazine-Based Compounds as a New Class of HIV-1 Entry Inhibitors. J. Med. Chem.; 2004 47(3); 768-768 35. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem., 1983 4, 187-217 36. Smellie, A. Poling: Promoting Conformational Variation. J. Comput. Chem., 1995 16, 171-187. 37. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Coverage. 1. Validation and Estimation of Coverage. J. Chem. Inf. Comput. Sci. 1995 35, 285-294 38. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Space. 2. Application of Conformational Models J. Chem. Inf. Comput. Sci. 1995 16, 295-304 39. Catalyst tutorials release 4.7; Accelrys, Inc. San Diego, 2002 40. http://www.hopkins-gi.org/pages/latin/templates/index.cfmTest 41. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22, 151-185. 42. Saladino, R.; Crestini, C.; Palamara, A. T.; Danti, M. C.; Manetti, F.; Corelli, F.; Garaci, E.; Botta, M. Synthesis, Biological Evaluation, and Pharmacophore Generation of Uracil, 4(3H)-Pyrimidone, and Uridine Derivates as Potent and Selective Inhibitors of Parainfluenza 1 (Sendai) Virus. J. Med. Chem. 2001, 44, 4554-4562. 43. Tafi, A.; Costi, R.; Botta, M.; Di Santo, R.; Corelli, F.; Massa, S.; Ciacci, A.; Manetti, F.; Artico, M. Antifungal Agents. 10. New Derivates of 1-[(Arly)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole,Synthesis, Anti-Candida Activity, and Quantitative Structure-Analysis Relationship Studies. J. Med. Chem. 2002, 45, 2720-2732. 44. Singh, J.; van Vlijmen, H.; Liao, Y.; Lee, W.; Cornebise, M.; Harris, M.; Shu, I.; Gill, A.; Cuervo, J. H.; Abraham, W. M.; Adams, S. P. Identification of Potent and Novel R4‚1 Antagonists Using in Silico Screening. J. Med. Chem. 2002, 45, 2988-2993. 45. Palomer, A.; Cabre, F.; Pascual, J.; Campos, J.; Trujillo, M. A.; Entrena, A.; Gallo, M. A.; Garcia, L.; Mauleon, D.; Espinosa, A. Identification of Novel Cyclooxygenase-2 Selective Inhibitors Using Pharmacophore Models. J. Med. Chem. 2002, 45, 1402-1411. 46. Ekins, S.; Kim, R. B.; Leake, B. F.; Dantzig, A. H.; Schuetz, E.G.; Lan, L.; Yasuda, K.; Shepard, R. L.; Winter, M. A.; Schuetz, J. D.; Wikel, J. H.; Wrighton, S. A. Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates. Mol. Pharmacol. 2002,61, 974-981. 47. Dziadulewicz, E. K.; Ritchie, T. J.; Hallett, A.; Snell, C. R.; Davies, J. W.; Wrigglesworth, R.; Dunstan, A. R.; Bloomfield, G. C.; Drake, G. S.; McIntyre, P.; Brown, M. C.; Burgess, G. M.;Lee, W.; Davis, L.; Yaqoob, M.; Phagoo, S. B.; Phillips, E.; Perkins, M. N.; Campbell, E. A.; Davis, A. J.; Rang, H. P. Nonpeptide Bradykinin B2 Receptor Antagonists: Conversion of Rodent-Selective Bradyzide Analogues into Potent, Orally Active Human Bradykinin B2 Receptor Antagonists. J. Med. Chem. 2001, 45, 2160-2172. 48. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fourier, A.; Klabunde, T. Identification of Nonpeptidic Urotensin II Receptor Antagonists by Virtual Screening Based on a Pharmacophore Model Derived from Structure-Activity Relationships and Nuclear Resonance Studies on Urotensin II. J. Med. Chem. 2002, 45, 1799-1805. 49. Kurogi, Y.; Miyata, K.; Okamura, T.; Hashimoto, K.; Tsutsumi, K.; Nasu, M.; Moriyasu, M. Discovery of Novel Mesangial Cell Proliferation Inhibitors Using a Three-Dimensional Database Searching Method. J. Med. Chem. 2001, 44, 2304-2307. 50. Chen, G. S.; Chang, C.; Kan, W. M.; Chang, C.; Wang, K. C.; Chern, J. Novel Lead Generation through Hypothetical Pharmacophore Three-Dimensional Database Searching: Discovery of Isoflavonoids as Nonsteroidal inhibitors of Rat 5R-Reductase. J. Med. Chem. 2001, 44, 3759-6763. 51. Palomer, A.; Pascual, J.; Cabre´, F.; Luisa, M.; Mauleo´n, D. Derivation of Pharmacophore and CoMFA Models for Leukotriene D4 Receptor Antagonists of the Quinolinyl(bridged)aryl Series. J. Med. Chem. 2000, 43, 392-400. 52. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky, M. L.; Anderson, S. D.; Lin, S. L. Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112. 53. Barbaro, R.; Betti, L.; Botta, M.; Corelli, F.; Giannacchini, G.; Maccari, L.; Manetti, F.; Strappaghetti, G.; Corsano, S. Synthesis, Biological Evaluation, and Pharmacophore Generation of New Pyridazinone Derivates with Affinity toward R1- and R2- Adrenoceptores. J. Med. Chem. 2001, 44, 2118-2132. 54. Ekins, S.; Durst, G. L.; Stratford, R. E.; Thorner, D. A.; Lewis, R.; Lonarich, R. J.; Wikel, J. H. Three-Dimensional Quantitative Structure-Permeability Relationship Analysis for a Series of Inhibitors of Rhinovirus Replication. J. Chem. Inf. Comput. Sci. 2001, 41, 1578-1586. 55. Bureau, R.; Daveu, C.; Lemaýˆtre, S.; Dauphin, F.; Landelle, H.; Lancelot, J.; Rault, S. Molecular Design Based on 3D-Pharmacophore. Application to 5-HT4 Receptor. J. Chem. Inf. Comput. Sci. 2002, 42, 962-967. 56. Glunz PW, Douty BD, Decicco CP. Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors. Bioorg Med Chem Lett. 2003 Mar 10;13(5):785-8. 57. Zhang X, Schmitt AC, Jiang W, Wasserman Z, Decicco CP. Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1157-60. 58. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem. 2004 Apr 23;279(17):17508-14. Epub 2004 Feb 06. 59. Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukolj G, LaPlante SR, Llinas-Brunet M, Nar H, Lamarre D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection Angew Chem Int Ed Engl. 2003 Mar 28;42(12):1356-60.; http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/28613Test
-
7مورد إلكتروني
المصدر: DTIC AND NTIS
مصطلحات الفهرس: Electrical and Electronic Equipment, Electric Power Production and Distribution, Computer Programming and Software, Test Facilities, Equipment and Methods, COMPUTER PROGRAMS, RESEARCH FACILITIES, PULSE GENERATORS, PULSES, TEST SETS, DIRECT CURRENT, SHORT PULSES, SWITCHES, HIGH VOLTAGE, VOLTAGE, LABORATORIES, WAVEFORM CATALYST PROGRAM, SIGNAL PROCESSING, DISPLAY SYSTEMS, ANALOG TO DIGITAL CONVERTERS., Text
